Iterum Therapeutics plc is a clinical-stage pharmaceutical company. It develops and markets therapies to address unmet medical needs, as well as provides anti-infectives to treat multi-drug resistant pathogens. The company's product pipeline consists of uncomplicated urinary tract infections, complicated urinary tract infections and complicated intra abdominal infections. Iterum Therapeutics plc is based in Dublin, Ireland.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-38.37M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -664.00% |
| Return on Assets (Trailing 12 Months) | -87.64% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.89 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.89 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 3.63 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.48 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.94 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.96 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.97 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 16.43M |
| Free Float | 15.54M |
| Market Capitalization | $25.95M |
| Average Volume (Last 20 Days) | 0.15M |
| Beta (Past 60 Months) | 2.36 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 9.21% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |